Caladrius Biosciences

Caladrius Biosciences 300x
Ex vivo expanded polyclonal T regulatory cell therapy 

Company Description

Caladrius Biosciences, Inc. is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications.
The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial.

https://www.caladrius.com/about/overview/

Go Back To Partners